Orexo: Zubsolv Rx data week 12

Research Update

2015-03-27

13:17

The latest Rx data, released today, shows a w/w decline in Zubsolv prescriptions and tablet sales. TRx market share were 5.51% and tablet sales market share were 6.10%. However, the four week rolling average Zubsolv tablet sales shows a consistent upward trend and the market share rose by 0.04 percentage points to 6.16%. TRx four week rolling average were more or less unchanged at 5.60%. The y/y overall buprenorphine/naloxone units sales were up by 10.4%.

KP

Klas Palin

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.